Immunocore Holdings plc (IMCR) shareholders
Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wellington Investment Advisors Holdings LLP Joint filing with Wellington Management Group LLP (11.60%), Wellington Group Holdings LLP (11.60%) and 1 more | 5,959,773 | 11.60% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Management Company LLP Joint filing with Wellington Management Group LLP (10.20%), Wellington Group Holdings LLP (10.20%) and 1 more | 5,132,898 | 10.00% | 13G (passive) amendment | Jul 31, 2025 |
| RTW Investments, LP Joint filing with Roderick Wong, M.D (9.70%) | 4,869,798 | 9.70% | 13G (passive) amendment | Sep 30, 2024 |
| Wellington Management Group LLP Joint filing with Wellington Group Holdings LLP (9.10%), Wellington Investment Advisors Holdings LLP (9.10%) and 1 more | 4,515,524 | 9.10% | 13G (passive) amendment | Jun 30, 2025 |
| Jallal Bahija | 4,493,139 | 8.20% | 13G (passive) | Dec 31, 2024 |
| Abigail P. Johnson Joint filing with FMR LLC (8.80%) | 4,307,246 | 8.80% | 13G (passive) amendment | Jun 30, 2026 |
| Primecap Management Co/Ca/ | 3,772,234 | 7.51% | 13G (passive) amendment | Jun 30, 2025 |
| Bellevue Asset Management AG Joint filing with Bellevue Group AG (5.60%) | 2,796,803 | 5.60% | 13G (passive) | Aug 20, 2025 |
| Vestal Point Capital, LP Joint filing with Ryan Wilder (5.50%) | 2,766,868 | 5.50% | 13G (passive) | Mar 31, 2026 |
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (5.20%), Point72 Capital Advisors, Inc. (5.20%) | 2,720,043 | 5.20% | 13G (passive) | Nov 6, 2026 |
| Kevin Tang Joint filing with Tang Capital Management, LLC (5.20%) | 2,605,608 | 5.20% | 13G (passive) | Oct 17, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMCR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Wellington Management Group Llp | 5,721,945 | 11.11% | $181.67M | +1,015,777 | 0.03% |
| Rtw Investments, LP | 4,869,798 | 9.46% | $154.62M | – | 1.32% |
| FMR LLC | 4,307,246 | 8.36% | $136.76M | −521,908 | 0.01% |
| Primecap Management Co/Ca/ | 3,638,241 | 7.06% | $115.51M | −55,000 | 0.07% |
| Bellevue Group AG | 2,788,245 | 5.41% | $88.53M | −8,558 | 1.86% |
| Tang Capital Management LLC | 2,649,368 | 5.14% | $84.12M | – | 3.82% |
| Vestal Point Capital, LP | 1,800,000 | 3.50% | $57.15M | −966,868 | 1.34% |
| Two Sigma Investments, LP | 1,648,983 | 3.20% | $52.36M | +627,718 | 0.04% |
| Millennium Management LLC | 1,597,037 | 3.10% | $50.71M | +359,634 | 0.02% |
| Armistice Capital, LLC | 1,428,000 | 2.77% | $45.34M | +240,000 | 0.55% |
| Caligan Partners LP | 1,381,317 | 2.68% | $43.86M | New | 2.06% |
| Kynam Capital Management, LP | 1,375,000 | 2.67% | $43.66M | +490,063 | 2.41% |
| Bvf Inc/Il | 1,294,463 | 2.51% | $41.10M | – | 1.05% |
| Acadian Asset Management LLC | 1,209,894 | 2.35% | $38.39M | +708,803 | 0.05% |
| Trails Edge Capital Partners, LP | 1,063,234 | 2.06% | $33.76M | +380,637 | 5.36% |
| BlackRock, Inc. | 1,004,598 | 1.95% | $31.90M | +348,289 | 0.00% |
| Point72 Asset Management, L.P. | 990,280 | 1.92% | $31.44M | −111,991 | 0.03% |
| Price T Rowe Associates Inc /Md/ | 831,068 | 1.61% | $26.39M | −88,264 | 0.00% |
| Jupiter Topco LLC | 709,022 | 1.38% | $22.50M | New | 0.01% |
| Cantor Fitzgerald, L. P. | 680,200 | 1.32% | $21.60M | +429,989 | 0.12% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 136 | 52M | 100.0% | 27 / 52 | 39 / 31 | 11M | 10M |
| Q1 2026 | 142 | 52M | 100.0% | 23 / 51 | 44 / 28 | 9M | 9M |
| Q4 2025 | 149 | 52M | 100.0% | 31 / 48 | 39 / 10 | 5M | 2M |
| Q3 2025 | 132 | 49M | 95.5% | 18 / 41 | 48 / 18 | 4M | 3M |
| Q2 2025 | 133 | 48M | 92.8% | 31 / 45 | 41 / 13 | 6M | 6M |
| Q1 2025 | 116 | 47M | 91.9% | 15 / 43 | 33 / 14 | 4M | 2M |
| Q4 2024 | 115 | 45M | 88.2% | 13 / 37 | 44 / 27 | 5M | 4M |
| Q3 2024 | 130 | 45M | 88.0% | 19 / 47 | 39 / 27 | 8M | 5M |
| Q2 2024 | 139 | 43M | 84.0% | 25 / 58 | 35 / 35 | 12M | 11M |
| Q1 2024 | 149 | 43M | 83.2% | 29 / 64 | 39 / 13 | 9M | 4M |
| Q4 2023 | 133 | 39M | 75.0% | 23 / 52 | 42 / 15 | 5M | 4M |
| Q3 2023 | 125 | 37M | 71.7% | 14 / 50 | 38 / 8 | 4M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
67 funds held IMCR in Q1 2026, 3% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IMCR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 4,246,274 | 8.25% | $143.57M | 0.38% | Jul 31, 2026 |
| Vanguard Capital Opportunity Fund | 2,335,650 | 4.54% | $74.16M | 0.23% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 1,121,692 | 2.18% | $32.41M | 0.03% | May 31, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 1,111,200 | 2.16% | $37.57M | 0.51% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 645,268 | 1.25% | $20.49M | 0.17% | Jun 30, 2026 |
| Select Health Care Portfolio | 500,000 | 0.97% | $14.45M | 0.25% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 330,328 | 0.64% | $9.54M | 0.03% | May 31, 2026 |
| MFS New Discovery Fund | 304,295 | 0.59% | $8.79M | 0.41% | May 31, 2026 |
| iShares Biotechnology ETF | 299,288 | 0.58% | $9.50M | 0.10% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 287,200 | 0.56% | $8.30M | 0.16% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 261,570 | 0.51% | $7.56M | 0.03% | May 31, 2026 |
| Fidelity Advisor Health Care Fund | 260,000 | 0.50% | $8.79M | 0.28% | Jul 31, 2026 |
| SmallCap Fund | 217,900 | 0.42% | $7.37M | 0.35% | Jul 31, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 188,691 | 0.37% | $5.45M | 0.09% | May 29, 2026 |
| Old Westbury Small & Mid Cap Strategies Fund | 159,882 | 0.31% | $5.41M | 0.06% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bahija Jallal | CHIEF EXECUTIVE OFFICER, Director | 12,343 | 0.02% | Feb 19, 2026 |
| Travis Alan Coy | Chief Financial Officer | – | – | Feb 19, 2026 |
| Leger Tina Amber St | CHIEF HR OFFICER | 1,119 | 0.00% | Feb 19, 2026 |
| David M. Berman | HEAD OF R&D | 5,859 | 0.01% | Feb 19, 2026 |
| John Goll | SVP, FINANCE & CAO | 653 | 0.00% | Feb 19, 2026 |
| Siddharth Kaul | Director | – | – | May 28, 2026 |
| Kristine Peterson | Director | – | – | May 28, 2026 |
| William Pao | Director | – | – | May 28, 2026 |
| Roy Steven Herbst | Director | – | – | May 28, 2026 |
| Peter John Ratcliffe | Director | 333 | 0.00% | May 28, 2026 |
| John Irving Bell | Director | 13,452 | 0.03% | May 28, 2026 |
| Julian Baker | Director | – | – | May 19, 2025 |
| Bros. Advisors Lp Baker | Director | – | – | May 19, 2025 |
| Bros. Advisors (GP) LLC Baker | Director | 1,405,421 | 2.73% | May 19, 2025 |
| Brothers Life Sciences LP Baker | Director | – | – | May 19, 2025 |
| 667, L.P. | Director | 2,051,711 | 3.98% | May 19, 2025 |
| Felix Baker | Director | – | – | May 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John Goll SVP, FINANCE & CAO | Feb 18, 2026 | Sale | −698 | $32.35 | $22.58K | 653 |
| David M. Berman HEAD OF R&D | Feb 18, 2026 | Sale | −5,965 | $32.35 | $192.97K | 5,859 |
| Bahija Jallal CHIEF EXECUTIVE OFFICER, Director | Feb 18, 2026 | Sale | −11,474 | $32.35 | $371.18K | 12,343 |
| Leger Tina Amber St CHIEF HR OFFICER | Feb 18, 2026 | Sale | −1,000 | $32.35 | $32.35K | 1,119 |
| John Goll SVP, FINANCE & CAO | Feb 17, 2026 | Option exercise | +1,351 | – | – | 1,351 |
| David M. Berman HEAD OF R&D | Feb 17, 2026 | Option exercise | +11,824 | – | – | 11,824 |
| Bahija Jallal CHIEF EXECUTIVE OFFICER, Director | Feb 17, 2026 | Option exercise | +23,817 | – | – | 23,817 |
| Leger Tina Amber St CHIEF HR OFFICER | Feb 17, 2026 | Option exercise | +2,119 | – | – | 2,119 |
| David M. Berman HEAD OF R&D | Dec 5, 2025 | Option exercise | +572 | $17.46 | $9.99K | 572 |
| David M. Berman HEAD OF R&D | Dec 5, 2025 | Sale(10b5-1 plan) | −572 | $40.14 | $22.96K | 0 |
| David M. Berman HEAD OF R&D | Dec 4, 2025 | Sale(10b5-1 plan) | −31,341 | $40.26 | $1.26M | 0 |
| David M. Berman HEAD OF R&D | Dec 4, 2025 | Option exercise | +31,341 | $17.46 | $547.21K | 31,341 |
| David M. Berman HEAD OF R&D | Nov 28, 2025 | Option exercise | +5,521 | $17.46 | $96.40K | 5,521 |
| David M. Berman HEAD OF R&D | Nov 28, 2025 | Sale(10b5-1 plan) | −5,521 | $40.09 | $221.34K | 0 |
| David M. Berman HEAD OF R&D | Nov 26, 2025 | Option exercise | +69,404 | $17.46 | $1.21M | 69,404 |
| David M. Berman HEAD OF R&D | Nov 26, 2025 | Sale(10b5-1 plan) | −69,404 | $40.12 | $2.78M | 0 |
| David M. Berman HEAD OF R&D | Nov 25, 2025 | Sale(10b5-1 plan) | −18,020 | $40.03 | $721.34K | 0 |
| David M. Berman HEAD OF R&D | Nov 25, 2025 | Option exercise | +18,020 | $17.46 | $314.63K | 18,020 |
| David M. Berman HEAD OF R&D | Nov 24, 2025 | Sale(10b5-1 plan) | −100 | $40.00 | $4.00K | 0 |
| David M. Berman HEAD OF R&D | Nov 24, 2025 | Option exercise | +100 | $17.46 | $1.75K | 100 |
| David M. Berman HEAD OF R&D | Sep 30, 2025 | Sale(10b5-1 plan) | −61,849 | $35.23 | $2.18M | 0 |
| David M. Berman HEAD OF R&D | Sep 30, 2025 | Option exercise | +61,849 | $17.46 | $1.08M | 61,849 |
| David M. Berman HEAD OF R&D | Sep 15, 2025 | Option exercise | +200 | $17.46 | $3.49K | 200 |
| David M. Berman HEAD OF R&D | Sep 15, 2025 | Sale(10b5-1 plan) | −200 | $35.01 | $7.00K | 0 |
| David M. Berman HEAD OF R&D | Sep 12, 2025 | Option exercise | +22,532 | $17.46 | $393.41K | 22,532 |
| David M. Berman HEAD OF R&D | Sep 12, 2025 | Sale(10b5-1 plan) | −21,232 | $35.63 | $756.50K | 1,300 |
| David M. Berman HEAD OF R&D | Sep 12, 2025 | Sale(10b5-1 plan) | −1,300 | $36.31 | $47.20K | 0 |
| David M. Berman HEAD OF R&D | Sep 11, 2025 | Sale(10b5-1 plan) | −19,081 | $36.28 | $692.26K | 0 |
| David M. Berman HEAD OF R&D | Sep 11, 2025 | Option exercise | +19,081 | $17.46 | $333.15K | 19,081 |
| David M. Berman HEAD OF R&D | Sep 10, 2025 | Option exercise | +31,338 | $17.46 | $547.16K | 31,338 |
| David M. Berman HEAD OF R&D | Sep 10, 2025 | Sale(10b5-1 plan) | −30,138 | $36.12 | $1.09M | 1,200 |
| David M. Berman HEAD OF R&D | Sep 10, 2025 | Sale(10b5-1 plan) | −1,200 | $36.77 | $44.12K | 0 |
| 667, L.P. Director | Mar 17, 2025 | Buy | +646,290 | $29.74 | $19.22M | 2,051,711 |
| 667, L.P. Director | Mar 17, 2025 | Buy | +8,589 | $29.56 | $253.89K | 178,596 |
| 667, L.P. Director | Mar 17, 2025 | Buy | +92,349 | $29.56 | $2.73M | 2,144,060 |
| 667, L.P. Director | Mar 17, 2025 | Buy | +60,110 | $29.74 | $1.79M | 170,007 |
| Leger Tina Amber St CHIEF HR OFFICER | Apr 1, 2024 | Sale(10b5-1 plan) | −4,375 | $64.06 | $280.26K | 0 |
| Leger Tina Amber St CHIEF HR OFFICER | Apr 1, 2024 | Option exercise | +4,375 | $29.87 | $130.68K | 4,375 |
| David M. Berman HEAD OF R&D | Feb 28, 2024 | Sale(10b5-1 plan) | −7,472 | $68.84 | $514.37K | 12,137 |
| David M. Berman HEAD OF R&D | Feb 28, 2024 | Sale(10b5-1 plan) | −10,937 | $69.73 | $762.64K | 1,200 |
| David M. Berman HEAD OF R&D | Feb 28, 2024 | Sale(10b5-1 plan) | −1,200 | $70.45 | $84.54K | 0 |
| David M. Berman HEAD OF R&D | Feb 28, 2024 | Option exercise | +36,509 | $17.46 | $637.45K | 36,509 |
| David M. Berman HEAD OF R&D | Feb 28, 2024 | Sale(10b5-1 plan) | −16,900 | $67.61 | $1.14M | 19,609 |
| David M. Berman HEAD OF R&D | Feb 27, 2024 | Sale(10b5-1 plan) | −4,448 | $69.45 | $308.91K | 50,490 |
| David M. Berman HEAD OF R&D | Feb 27, 2024 | Sale(10b5-1 plan) | −3,394 | $71.97 | $244.27K | 0 |
| David M. Berman HEAD OF R&D | Feb 27, 2024 | Sale(10b5-1 plan) | −25,944 | $71.32 | $1.85M | 3,394 |
| David M. Berman HEAD OF R&D | Feb 27, 2024 | Sale(10b5-1 plan) | −21,152 | $70.42 | $1.49M | 29,338 |
| David M. Berman HEAD OF R&D | Feb 27, 2024 | Option exercise | +54,938 | $17.46 | $959.22K | 54,938 |
| David M. Berman HEAD OF R&D | Feb 26, 2024 | Option exercise | +28,553 | $17.46 | $498.54K | 28,553 |
| David M. Berman HEAD OF R&D | Feb 26, 2024 | Sale(10b5-1 plan) | −26,516 | $70.60 | $1.87M | 2,037 |
| David M. Berman HEAD OF R&D | Feb 26, 2024 | Sale(10b5-1 plan) | −2,037 | $71.31 | $145.26K | 0 |
| Leger Tina Amber St Chief HR Officer | Jan 3, 2024 | Option exercise | +4,375 | $29.87 | $130.68K | 4,375 |
| Leger Tina Amber St Chief HR Officer | Jan 3, 2024 | Sale(10b5-1 plan) | −4,068 | $69.85 | $284.15K | 307 |
| Leger Tina Amber St Chief HR Officer | Jan 3, 2024 | Sale(10b5-1 plan) | −307 | $70.46 | $21.63K | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Immunocore's stock actually held short. Settlement fails (shares not delivered on time) peaked at 19,780 shares on Aug 20, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David M. Berman Affiliate | May 22, 2026 | 69,271 | $2.04M | May 22, 2026 | Same Day Cashless Exercise and Sale |
| David M. Berman Affiliate | May 21, 2026 | 65,000 | $1.89M | May 21, 2026 | Same Day Cashless Exercise and Sale |
| David M. Berman Affiliate | Apr 8, 2026 | 25,000 | $796.25K | Apr 8, 2026 | Same Day Cashless Exercise and Sale |
| David M. Berman affiliate | Mar 11, 2026 | 11,832 | $385.33K | Mar 11, 2026 | Same Day Cashless Exercise and Sale |
| David M. Berman affiliate | Feb 18, 2026 | 5,965 | $192.95K | Feb 18, 2026 | RSU Vest |
| Leger Tina Amber St affiliate | Feb 18, 2026 | 1,000 | $32.35K | Feb 18, 2026 | RSU Vest |
| Bahija Jallal affiliate | Feb 18, 2026 | 11,474 | $371.15K | Feb 18, 2026 | RSU Vest |
| David M. Berman Officer | Nov 24, 2025 | 136,790 | $5.38M | Nov 24, 2025 | Stock Option Exercise |
| David M. Berman Officer | Sep 10, 2025 | 135,000 | $4.94M | Sep 10, 2025 | Stock Option Exercise |
| Donato Brian Di affiliate | Mar 17, 2025 | 100,000 | $3.00M | Mar 17, 2025 | Same Day Cashless Option Exercise and Sale |
| Donato Brian Di affiliate | Mar 14, 2025 | 56,250 | $1.64M | Mar 14, 2025 | Same Day Cashless Option Exercise and Sale |
| Leger Tina Amber St affiliate | Apr 1, 2024 | 4,375 | $280.28K | Apr 1, 2024 | Same Day Cashless Exercise and Sale |
| David M. Berman affiliate | Feb 26, 2024 | 120,000 | $8.48M | Feb 26, 2024 | Same Day Cashless Exercise and Sale |
| Leger Tina Amber St affiliate | Jan 3, 2024 | 4,375 | $262.50K | Jan 3, 2024 | Same Day Cashless Exercise and Sale |
| Bahija Jallal affiliate | Dec 27, 2023 | 25,000 | $1.75M | Dec 27, 2023 | Same Day Cashless Exercise and Sale |
See a number that looks wrong?